Accretion Pharmaceuticals IPO Review & Recommendations

Accretion Pharmaceuticals IPO Peer Comparison

Accretion Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 28, 2024)

Source: The Company's Financial Figures are based on restated standalone audited financial statements for the period ended on July 20, 2024 unless provided otherwise. Concerning Industry peers, all the financial information mentioned above is on a standalone basis. It is sourced from the audited results of the respective companies for the year ended March 31, 2024 unless provided otherwise.

Notes for peer group:

• The P/E Ratio has been computed based on the closing market price of equity shares on the NSE on May 05, 2025 (except for Sotac Pharmaceuticals Limited, which is taken as on April 24, 2025) divided by the Basic EPS as at March 31, 2024.
• Return on Net Worth (%) = net profit after tax divided by net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus/Other Equity as on March 31, 2024.
• NAV is computed as the closing net worth as on March 31, 2024, divided by the outstanding number of equity shares as on March 31, 2024.